Ascendis Pharma A/S Sees Unusually Large Options Volume (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND) saw unusually large options trading activity on Thursday. Investors acquired 2,359 call options on the stock. This is an increase of approximately 1,313% compared to the average daily volume of 167 call options.

Shares of NASDAQ ASND traded down $0.79 during midday trading on Friday, hitting $103.78. The company’s stock had a trading volume of 23,394 shares, compared to its average volume of 202,170. The business’s fifty day simple moving average is $113.12 and its two-hundred day simple moving average is $115.49. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.59 and a quick ratio of 11.59. Ascendis Pharma A/S has a 1 year low of $53.21 and a 1 year high of $133.96. The firm has a market capitalization of $4.44 billion, a price-to-earnings ratio of -27.55 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, August 28th. The biotechnology company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.08). Ascendis Pharma A/S had a negative net margin of 932.52% and a negative return on equity of 35.99%. The business had revenue of $3.61 million during the quarter, compared to analysts’ expectations of $0.68 million. Analysts anticipate that Ascendis Pharma A/S will post -5.31 EPS for the current fiscal year.



Several research analysts have recently commented on ASND shares. Zacks Investment Research raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, August 27th. Canaccord Genuity raised their price objective on shares of Ascendis Pharma A/S from $133.00 to $144.00 and gave the company a “buy” rating in a research note on Friday, May 31st. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $143.00 to $152.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. BidaskClub lowered shares of Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research note on Thursday. Finally, Wedbush reissued a “buy” rating and issued a $223.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, June 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Ascendis Pharma A/S has an average rating of “Buy” and a consensus target price of $153.29.

A number of institutional investors have recently modified their holdings of the stock. LPL Financial LLC lifted its stake in Ascendis Pharma A/S by 6.2% in the second quarter. LPL Financial LLC now owns 2,233 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 131 shares during the last quarter. Flinton Capital Management LLC lifted its stake in Ascendis Pharma A/S by 6.7% in the second quarter. Flinton Capital Management LLC now owns 2,304 shares of the biotechnology company’s stock worth $265,000 after acquiring an additional 144 shares during the last quarter. Aperio Group LLC raised its holdings in Ascendis Pharma A/S by 3.3% during the second quarter. Aperio Group LLC now owns 4,582 shares of the biotechnology company’s stock worth $528,000 after purchasing an additional 147 shares in the last quarter. Comerica Bank raised its holdings in Ascendis Pharma A/S by 7.8% during the second quarter. Comerica Bank now owns 2,460 shares of the biotechnology company’s stock worth $277,000 after purchasing an additional 179 shares in the last quarter. Finally, Meadow Creek Investment Management LLC raised its holdings in Ascendis Pharma A/S by 6.7% during the second quarter. Meadow Creek Investment Management LLC now owns 3,168 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 198 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: What are trading strategies for the 52-week high/low?

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.